Conditions: Nonsquamous Non-Small Cell Neoplasm of Lung Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer Stage IIIB
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 52
Healthy volunteers: no

Brief summary:
The main purpose for this study is to answer the following research questions:

* Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting?
* Will the participant be satisfied with home care?
* How might this impact the participant's quality of life?
* What are the required medical resources needed to give pemetrexed in a home setting?

Detailed description:

Arms:
arm 1: 500 milligrams per square meter (mg/m\^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.

Interventions: intervention 1: Pemetrexed
Intervention descriptions: intervention 1: Administered intravenously

Protocol document: